TIBO R82150 | 126320-77-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯二氮卓类
• 英文名称: TIBO R82150
• 英文别名: (11S)-11-methyl-10-(3-methylbut-2-enyl)-1,3,10-triazatricyclo[6.4.1.04,13]trideca-4,6,8(13)-triene-2-thione
• CAS: 126320-77-2
• 化学式: C₁₆H₂₁N₃S
• 分子量: 287.429
• InChiKey: WTTIBCHOELPGFK-LBPRGKRZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  50.6
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  N-((S)-1-Carbamoyl-ethyl)-2-chloro-3-nitro-benzamide 在 palladium on activated charcoal 、 dimethyl sulfide borane 、 氢气 、 potassium carbonate 作用下， 以 四氢呋喃 为溶剂， 反应 17.0h， 生成 TIBO R82150
  参考文献：
  名称：

  A four-step synthesis of TIBO R82150

  摘要：

  An efficient, four-step synthesis of the novel HIV-1 reverse transcriptase inhibitor TIBO R82150 is described.

  DOI：

  10.1021/jo00015a007

文献信息

• Phospho-indoles as HIV inhibitors
  申请人：Storer Richard

  公开号：US20060074054A1

  公开（公告）日：2006-04-06

  3-phosphoindole compounds for the treatment of retroviral infections, and particularly for HIV, are described. Also included are compositions comprising the 3-phosphoindole derivatives alone or in combination with one or more other anti-retroviral agents, processes for their preparation, and methods of manufacturing a medicament incorporating these compounds.

  描述了用于治疗逆转录病毒感染，特别是HIV的3-磷酸吲哚化合物。还包括仅含有3-磷酸吲哚衍生物或与一个或多个其他抗逆转录病毒药物组合的组合物，它们的制备过程，以及制造包含这些化合物的药物的方法。
• NUCLEOSIDE PHOSPHONATE DERIVATIVES
  申请人：Or Yat Sun

  公开号：US20090274686A1

  公开（公告）日：2009-11-05

  The present invention discloses compounds of formula (I) or (II), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit, preventing or treating abnormal cellular proliferation and/or a viral infection, particularly by HIV, HCV or HBV. Consequently, the compounds of the present invention interfere with the replication cycle of a virus and are also useful as antiviral agents, or interfere with host cellular biochemical process and are also useful as antiproliferative agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from viral infection and/or cell proliferation. The invention also relates to methods of treating a viral infection and/or cell proliferation in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention relates to novel antiviral/anti-proliferative compounds represented herein above, pharmaceutical compositions comprising such compounds, and methods for the treatment or prophylaxis of viral infection in a subject in need of such therapy with said compounds.

  本发明揭示了化合物的公式(I)或(II)，或其药学上可接受的盐、酯或前药：这些化合物抑制、预防或治疗异常细胞增殖和/或病毒感染，特别是HIV、HCV或HBV。因此，本发明的化合物干扰病毒的复制周期，同时也可用作抗病毒剂，或干扰宿主细胞的生化过程，同时也可用作抗增殖剂。本发明还涉及包含上述化合物的药物组合物，用于治疗患有病毒感染和/或细胞增殖的受试者。该发明还涉及通过给予包含本发明化合物的药物组合物来治疗受试者的病毒感染和/或细胞增殖的方法。本发明涉及上述新型抗病毒/抗增殖化合物，包括含有这些化合物的药物组合物，以及用于治疗或预防受试者的病毒感染的方法。
• Phenylindoles for the treatment of HIV
  申请人：——

  公开号：US20020193415A1

  公开（公告）日：2002-12-19

  The invention as disclosed herein is a method and composition for the treatment of HIV in humans and other host animals, that includes the administration of an effective HIV treatment amount of a phenylindole as described herein or a pharmaceutically acceptable salt or prodrug thereof, optionally in a pharmaceutically acceptable carrier. The compounds of this invention either possess antiviral (i.e., anti-HIV) activity, or are metabolized to a compound that exhibits such activity.

  本发明公开了一种用于治疗人类和其他宿主动物体内的HIV的方法和组合物，包括根据本文所述的给予有效的HIV治疗量的苯基吲哚或其药学上可接受的盐或前药，可选地在药学上可接受的载体中。本发明的化合物具有抗病毒（即抗HIV）活性，或者经代谢后形成具有该活性的化合物。
• 2'-CHLOROACETYLENYL SUBSTITUTED NUCLEOSIDE DERIVATIVES
  申请人：Wang Guoqiang

  公开号：US20130078217A1

  公开（公告）日：2013-03-28

  The present invention relates to 2′-chloroacetylenyl-substituted nucleoside derivatives of the general formula (I): As well as pharmaceutical compositions comprising such compounds and methods to treat or prevent an HIV infection, HBV infection, HCV infection or abnormal cellular proliferation, comprising administering said compounds or compositions. In addition, the present invention includes processes for the preparation of such compounds, and the related β-D and β-L-nucleoside derivatives.

  本发明涉及通式（I）的2'-氯乙炔基取代核苷衍生物，以及包含这些化合物的药物组合物和治疗或预防HIV感染、HBV感染、HCV感染或异常细胞增殖的方法，包括给予这些化合物或组合物。此外，本发明还包括用于制备这些化合物的方法，以及相关的β-D和β-L-核苷衍生物。
• [EN] NUCLEOSIDE AND NUCLEOTIDE DERIVATIVES<br/>[FR] DÉRIVÉS DE NUCLÉOSIDES ET DE NUCLÉOTIDES
  申请人：ENANTA PHARM INC

  公开号：WO2016033164A1

  公开（公告）日：2016-03-03

  The present invention discloses compounds of formula (I), or a pharmaceutically acceptable salt thereof: (I) which inhibit, preventing or treating abnormal cellular proliferation and/or a viral infection, particularly by HIV, HCV or HBV. Consequently, the compounds of the present invention interfere with the replication cycle of a virus and are also useful as antiviral agents, or interfere with host cellular biochemical process and are also useful as antiproliferative agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from viral infection and/or cell proliferation. The invention also relates to methods of treating a viral infection and/or cell proliferation in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention relates to novel antiviral/anti-proliferative compounds represented herein above, pharmaceutical compositions comprising such compounds, and methods for the treatment or prophylaxis of viral infection in a subject in need of such therapy with said compounds.

  本发明揭示了化合物(I)或其药学上可接受的盐，该化合物可抑制、预防或治疗异常细胞增殖和/或病毒感染，特别是HIV、HCV或HBV感染。因此，本发明的化合物干扰病毒的复制周期，也可用作抗病毒剂，或干扰宿主细胞的生化过程，也可用作抗增殖剂。本发明还涉及包含上述化合物的制药组合物，用于治疗患有病毒感染和/或细胞增殖的受试者。本发明还涉及通过给予包含本发明化合物的制药组合物来治疗受试者的病毒感染和/或细胞增殖的方法。本发明涉及上述新型抗病毒/抗增殖化合物，包括这些化合物的制药组合物，以及使用这些化合物治疗或预防受需要的受试者的病毒感染的方法。